NCT04313088View on ClinicalTrials.gov

Investigation of Eluxadoline for Diabetic Diarrhea

PHASE2/PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 1, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2024

Conditions
Diabetic DiarrheaDiabetesDiarrhea
Interventions
DRUG

Eluxadoline 100 mg

Eluxadoline 100mg by mouth twice daily with food

Trial Locations (1)

19140

Temple University Hospital, Philadelphia

Sponsors

Collaborators (1)

Allergan
All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

Temple University

OTHER

NCT04313088 - Investigation of Eluxadoline for Diabetic Diarrhea | Biotech Hunter | Biotech Hunter